金河生物科技股份有限公司2025年第一季度报告

Core Viewpoint - The company, Jinhe Biological Technology Co., Ltd., has released its annual report for 2024, highlighting its business performance, financial status, and future development plans, including a profit distribution proposal for shareholders [1][3]. Company Overview - Jinhe Biological aims to become a leading global animal health enterprise, focusing on veterinary pharmaceuticals and vaccines while expanding into new markets [4]. - The company's main business segments include animal health products, environmental wastewater treatment, and agricultural product processing [4][11]. Financial Performance - In 2024, the company achieved operating revenue of 2,370.63 million yuan, a year-on-year increase of 9.04% [28]. - The operating profit was 98.55 million yuan, a decrease of 5.90% compared to the previous year [28]. - The net profit attributable to shareholders was 100.20 million yuan, reflecting a year-on-year growth of 15.90% [28]. Profit Distribution Proposal - The board approved a profit distribution plan, proposing a cash dividend of 1.00 yuan per 10 shares (tax included) to all shareholders, with no bonus shares or capital reserve fund conversion [3][31][32]. Share Buyback and Stock Options - The company initiated a share buyback program with a total fund of no less than 50 million yuan and no more than 100 million yuan, completing the buyback of 15,221,500 shares by October 10, 2024 [14]. - A stock option incentive plan was approved, granting 11.75 million stock options to 25 incentive targets [15]. Strategic Partnerships - The company signed a strategic cooperation agreement with Shanghai Jiao Tong University to enhance collaboration in technological innovation and talent cultivation [16]. Subsidiary Adjustments - The board approved a reduction in the registered capital of a subsidiary, Animal Nutrition, from 20 million yuan to 6.6 million yuan, which will no longer be included in the consolidated financial statements [17].